Wnt-5b polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Wnt-5b polypeptides and polynucleotides in therapy, and diagnostic assays for such.

HTEGU07 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HTEGU07 polypeptides and polynucleotides in therapy, and diagnostic assays for such.

There are provided novel compounds of formula (I) ##STR1## wherein A represents an aromatic carbocyclic ring or a 5- or 6-membered heterocyclic aromatic ring containing 1 to 3 heteroatoms which may be the same or different and are selected from O, N and S; X represents --(CH.sub.2).sub.n -- wherein n represents zero or 1; and R.sup.1, R.sup.2 and R.sup.3 are as defined in the specification, and pharmaceutically acceptable salts thereof, and enantiomers and tautomers thereof; together with proces...

HE8AN36 potypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HE8AN36 polypeptides and polynucleotides in therapy, and diagnostic assays for such.

The present invention relates to novel compounds, and therapeutically acceptable salts thereof of the formula (I), which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases. ##STR1##

The present invention therefore provides, in a first aspect, a compound of formula (I) or a salt thereof: ##STR1## in which the group D is selected from a group of formula (A), (B) or (C) below: ##STR2## in which P is a monocyclic, bicyclic or tricyclic alicyclic ring containing up to 20 carbon atoms in the ring(s); A is a single bond, a C.sub.1-6 alkylene or a C.sub.2-6 alkenylene group; R.sup.1 is halogen, C.sub.1-6 alkyl optionally substituted by one or more fluorine atoms, C.sub.3-6 cycloalk...

There are provided pharmaceutical compounds useful in treating hypertension, heart diseases and renal failure. These compounds are 4-hydroxy phenethylamines wherein the 3 position on the phenyl nucleus is occupied by either an amino, amide, carbamyl, urea sulfonamide, substituted alkyl or fluorine atom, and the amine group is further linked to another phenyl radical through an alkylene radical which may contain nitrogen, oxygen, sulfur or cyclic hydrocarbon radicals as intervening groups.

Compounds of general Formula I: ##STR1## are presented which have collagenase inhibition activity and are useful in the management of disease involving tissue degradation and the promotion of wound healing. Representative diseases involving include arthropathy (particularly rheumatoid arthritis), inflammation, dermatological diseases, bone resorption disease and tumor invasion.

The invention provides Response Regulator polypeptides and DNA (RNA) encoding Response Regulator polypetides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing Response Regulator polypeptides to screen for antibacterial compounds.

The invention provides Response regulator polypeptides and DNA (RNA) encoding Response regulator polypetides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing Response regulator polypeptides to screen for antibacterial compounds.